Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More
CADILA HEALTHCARE | TORRENT PHARMA | CADILA HEALTHCARE/ TORRENT PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 28.2 | 37.4 | 75.4% | View Chart |
P/BV | x | 4.5 | 9.5 | 48.0% | View Chart |
Dividend Yield | % | 0.8 | 0.6 | 118.1% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CADILA HEALTHCARE Mar-20 |
TORRENT PHARMA Mar-19 |
CADILA HEALTHCARE/ TORRENT PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 352 | 1,964 | 17.9% | |
Low | Rs | 207 | 1,245 | 16.6% | |
Sales per share (Unadj.) | Rs | 139.2 | 453.4 | 30.7% | |
Earnings per share (Unadj.) | Rs | 11.8 | 25.8 | 45.6% | |
Cash flow per share (Unadj.) | Rs | 18.6 | 62.3 | 29.8% | |
Dividends per share (Unadj.) | Rs | 3.50 | 17.00 | 20.6% | |
Dividend yield (eoy) | % | 1.3 | 1.1 | 118.2% | |
Book value per share (Unadj.) | Rs | 101.4 | 279.2 | 36.3% | |
Shares outstanding (eoy) | m | 1,023.74 | 169.22 | 605.0% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.0 | 3.5 | 56.7% | |
Avg P/E ratio | x | 23.7 | 62.2 | 38.2% | |
P/CF ratio (eoy) | x | 15.0 | 25.8 | 58.4% | |
Price / Book Value ratio | x | 2.8 | 5.7 | 48.0% | |
Dividend payout | % | 29.8 | 65.9 | 45.1% | |
Avg Mkt Cap | Rs m | 286,033 | 271,513 | 105.3% | |
No. of employees | `000 | 13.4 | 13.6 | 98.6% | |
Total wages/salary | Rs m | 24,145 | 14,038 | 172.0% | |
Avg. sales/employee | Rs Th | 10,632.7 | 5,642.6 | 188.4% | |
Avg. wages/employee | Rs Th | 1,801.2 | 1,032.4 | 174.5% | |
Avg. net profit/employee | Rs Th | 898.5 | 320.9 | 280.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 142,531 | 76,728 | 185.8% | |
Other income | Rs m | 1,139 | 571 | 199.6% | |
Total revenues | Rs m | 143,670 | 77,299 | 185.9% | |
Gross profit | Rs m | 24,198 | 19,831 | 122.0% | |
Depreciation | Rs m | 6,965 | 6,177 | 112.8% | |
Interest | Rs m | 3,418 | 5,038 | 67.9% | |
Profit before tax | Rs m | 14,954 | 9,187 | 162.8% | |
Minority Interest | Rs m | 288 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -3,570 | 0.0% | |
Tax | Rs m | 3,198 | 1,254 | 255.1% | |
Profit after tax | Rs m | 12,044 | 4,363 | 276.0% | |
Gross profit margin | % | 17.0 | 25.8 | 65.7% | |
Effective tax rate | % | 21.4 | 13.6 | 156.7% | |
Net profit margin | % | 8.5 | 5.7 | 148.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,154 | 50,375 | 173.0% | |
Current liabilities | Rs m | 82,694 | 51,653 | 160.1% | |
Net working cap to sales | % | 3.1 | -1.7 | -187.9% | |
Current ratio | x | 1.1 | 1.0 | 108.1% | |
Inventory Days | Days | 71 | 92 | 77.6% | |
Debtors Days | Days | 94 | 68 | 137.4% | |
Net fixed assets | Rs m | 133,236 | 83,648 | 159.3% | |
Share capital | Rs m | 1,024 | 846 | 121.0% | |
"Free" reserves | Rs m | 102,733 | 46,397 | 221.4% | |
Net worth | Rs m | 103,757 | 47,244 | 219.6% | |
Long term debt | Rs m | 32,146 | 39,129 | 82.2% | |
Total assets | Rs m | 236,866 | 141,209 | 167.7% | |
Interest coverage | x | 5.4 | 2.8 | 190.4% | |
Debt to equity ratio | x | 0.3 | 0.8 | 37.4% | |
Sales to assets ratio | x | 0.6 | 0.5 | 110.7% | |
Return on assets | % | 6.5 | 6.7 | 98.1% | |
Return on equity | % | 11.6 | 9.2 | 125.7% | |
Return on capital | % | 13.7 | 12.3 | 111.3% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 52,752 | 22,103 | 238.7% | |
Fx outflow | Rs m | 14,504 | 5,522 | 262.7% | |
Net fx | Rs m | 38,248 | 16,581 | 230.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 25,054 | 17,981 | 139.3% | |
From Investments | Rs m | -10,123 | -2,413 | 419.6% | |
From Financial Activity | Rs m | -10,942 | -13,145 | 83.2% | |
Net Cashflow | Rs m | 3,989 | 2,380 | 167.6% |
Indian Promoters | % | 74.8 | 71.5 | 104.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.3 | 7.0 | 118.2% | |
FIIs | % | 5.9 | 12.6 | 46.8% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 11.0 | 8.8 | 125.0% | |
Shareholders | 44,069 | 26,511 | 166.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CADILA HEALTHCARE With: VENUS REMEDIES SHASUN PHARMA PFIZER J.B.CHEMICALS NEULAND LABS
Compare CADILA HEALTHCARE With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Extending losses to the fifth straight session, Indian share markets witnessed selling pressure throughout the day today and ended deep in the red.
For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More